EU/3/06/419: Orphan designation for the treatment of pancreatic cancer


Table of contents


On 31 October 2006, orphan designation (EU/3/06/419) was granted by the European Commission to MediGene AG, Germany, for paclitaxel (liposomal) for the treatment of pancreatic cancer.

The sponsorship was transferred to SynCore Biotechnology Europe GmbH, Germany, in June 2016.

Key facts

Active substance
Intended use
Treatment of pancreatic cancer
Orphan designation status
EU designation number
Date of designation
SynCore Biotechnology Europe GmbH
c/o Hogan Lovells International LLP
Karl-Scharnagl-Ring 5
80539 Munich
Tel. +49 89 29 01 20
Fax +49 89 29 01 22 22

Documents related to this orphan designation evaluation

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

EU register of orphan medicines

The list of medicines that have received an orphan designation in the EU is available on the European Commission's website:

How useful was this page?

Add your rating